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Erythroid progenitor cellSRPK1, the prototype of the serine/arginine family of kinases, has been implicated in the regulation of
multiple cellular processes such as pre-mRNA splicing, chromatin structure, nuclear import and germ cell
development. SRPK1a is a much less studied isoform of SRPK1 that contains an extended N-terminal domain
and so far has only been detected in human testis. In the present study we show that SRPK1 is the
predominant isoform in K562 cells, with the ratio of the two isoforms being critical in determining cell fate.
Stable overexpression of SRPK1a induces erythroid differentiation of K562 cells. The induction of globin
synthesis was accompanied by a marked decrease in proliferation and a signiﬁcantly reduced clonogenic
potential. Small interfering RNA-mediated down-regulation of SRPK1 in K562 cells results similarly in a
decrease in proliferative capacity and induction of globin synthesis. A decreased SRPK1/SRPK1a ratio is also
observed upon hemin/DMSO-induced differentiation of K562 cells as well as in normal human erythroid
progenitor cells. Mass spectrometric analysis of SRPK1a-associated proteins identiﬁed multiple classes of
RNA-binding proteins including RNA helicases, heterogeneous nuclear ribonucleoproteins, ribosomal
proteins, and mRNA-associated proteins. Several of the SRPK1a-copurifying proteins have been previously
identiﬁed in ribosomal and pre-ribosomal complexes, thereby suggesting that SRPK1a may play an
important role in linking ribosomal assembly and/or function to erythroid differentiation in human
leukaemic cells.erine; SRPK, serine/arginine
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Serine/Arginine protein kinases (SRPKs) that phosphorylate SR/
RS dipeptide-containing proteins have been conserved throughout
evolution and so far approximately 15 distinct genes encoding
members of this family have been identiﬁed in the genomes of
mammals, yeast, fruit ﬂy, nematode, and plants [1,2].The SRPK family is represented by four members in humans:
SRPK1 (named also SRPK1 isoform 2 according to UniProtKB/Swiss-
Prot Q96SB4), SRPK1a (named also SRPK1 isoform 1 according to
UniProtKB/Swiss-Prot Q96SB4), SRPK2 and SRPK3. SRPK1 was
mapped to chromosome 6p21.2–p21.3 [3]. Splicing out of a 513-
bp segment, which is located between the ﬁrst two exons of the
SRPK1 locus, results in the production of SRPK1, whereas splicing in
of the 513-bp segment yields its isoform SRPK1a [2]. SRPK1 is
predominantly expressed in testis, but is also present in detectable
levels in most tissues [4,5] (see also Gene Expression Atlas
databank, http://expression.gnf.org/cgi-bin/index.cgi), while so far
SRPK1a was only seen in testis [2]. SRPK2 was mapped to
chromosome 7q22–q31.1 [3] and its levels are high in testis and
brain [5] (see also Gene Expression Atlas). SRPK3 (also known as
STK23) is speciﬁcally expressed in the heart and skeletal muscle [1].
SRPK3-null mice display type 2 ﬁber-speciﬁc myopathy with a
marked increase in centrally placed nuclei, while transgenic mice
overexpressing SRPK3 showed severe myoﬁber degeneration and
early lethality [1].
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SRPKswas based on SRPK1. SR proteins thatmediate both constitutive
and alternative splicing of pre-mRNAs, lamin B receptor (LBR), an
integral protein of the inner nuclear membrane and protamine 1, a
small basic arginine-rich protein that replaces histones during the
development of mature spermatozoa, have been the most extensively
studied cellular substrates of SRPK1 [4–8]. Phosphorylation of SR
proteins is required for their recruitment to sites of transcription
[9,10], promotes spliceosome assembly [11], and mediates the
interaction of SR proteins with the C-terminal domain of polymerase
II to coordinate transcription with splicing [10]. It has also been
proposed that phosphorylation of SR proteins in the cytoplasmmay act
as a switch between mRNA unloading and SR protein reimport to the
nucleus [12,13]. LBR is one of the key factors that have been implicated
in chromatin anchorage to the nuclear envelope [14,15]. Takano et al.
[16,17] have shown that SRPK1-mediated phosphorylation affects
LBR association with chromatin. Phosphorylation of protamine 1 is
required for its transient docking to the nuclear envelope, which is an
important intermediate step that directs the proper deposition of
protamine molecules into sperm chromatin [4,18,19].
Previous studies have shown that SRPK1, SRPK1a and SRPK2 are
mainly localized in the cytoplasm and to a lesser extent in the nucleus,
despite having putative nuclear localization signals [2,4,5,20,21]. A
unique spacer sequence in each kinase, dividing conserved catalytic
kinase domains into two halves, seems to be responsible for their
cytoplasmic distribution [20]. It was recently shown that this spacer
domain, together with yet uncharacterized SRPK1 sequences, mediate
the attachment of the kinase to the Hsp70/Hsp90 machinery, thereby
functioning as a docking motif to restrict SRPK1 in the cytoplasm [22].
Cytoplasmic SRPKs may be responsible for initial SR protein
phosphorylation that is critical for their interaction with transportin
and their subsequent import into the nucleus [13]. However, the
presence of SRPKs in the cytoplasm may also reﬂect a variety of yet
unidentiﬁed roles of these kinases, in addition to their nuclear
functions. Interestingly, a cell cycle signal induces nuclear transloca-
tion of SRPK1 and its ﬁssion yeast homologue dsk1 at the G2/M
boundary [20,23].
In the present study we noticed that SRPKs are highly expressed in
different erythroid and lymphoid cell lines, with SRPK1 mRNA being
farmore abundant than SRPK1a. Using K562 human leukaemic cells as
a model system, we demonstrated that the ratio of SRPK1/SRPK1a
plays a decisive role in determining cell fate. Stable overexpression of
SRPK1a or siRNA-mediated down-regulation of SRPK1 in K562 cells
results in a substantial induction of globin synthesis. The observed
erythroid differentiation is accompanied by growth inhibition and a
signiﬁcantly reduced clonogenic potential, as compared to the
parental cells. A similar decreased SRPK1/SRPK1a ratio is also
observed following hemin/DMSO-induced differentiation of K562
cells as well as in normal human erythroid progenitor cells. Over-
expressed SRPK1a was found to localize in the P100 fraction,
cytoplasm and nuclear matrix and associate with a variety of RNA
binding proteins, many of which have been previously identiﬁed in
pre-ribosomal and ribosomal complexes. In view of the fact that none
of the proteins co-purifying with SRPK1a is directly phosphorylated
by the kinase due to the lack of RS domain(s), we discuss the potential
association of SRPK1a-containing complexes with erythroid
differentiation.
2. Materials and methods
2.1. K562 and primary erythroid cells culture, induction of differentiation
K562 cells were maintained in RPMI medium supplemented with
10% (v/v) fetal calf serumwith antibiotics. Cell growthwasmonitored
by determining the cell number/ml with the use of a Coulter counter
model ZBI. For induction of differentiation, exponentially growingK562 cells were seeded at 1×105 cells/ml in the presence of 60 μM
hemin and 1.5% DMSO. The induction period was 4 days without
changing the medium. Hemoglobin-containing cells were detected by
staining the cells with a benzidine-peroxide solution [24].
Primary erythroid cells were isolated from cord blood as
previously described [25]. Cells were maintained in StemSpan
Serum-Free Expansion Medium (SFEM) (StemCell Technologies)
supplemented with 2 U/ml erythropoietin (Janssen-Cilag, 10,000 U/
ml), 100 ng/ml Stem Cell Factor, 10−6 M dexamethasone, 40 ng/ml
Insulin-like Growth Factor-1 and 20 μg/ml of a cholesterol-rich lipid
mix (all from Sigma) at a concentration of approximately 2 million
cells per ml. At day 14, more than 95% of the cells showed the
characteristics of erythroid progenitors in haematological staining,
cell diameter and ﬂow cytometry (N95% of the cells were positive for
CD71 and CD36). Terminal erythroid differentiation was induced on
day 14 by seeding the cells in StemSpan SFEM supplemented with 10
U/ml erythropoietin, insulin 4×10−4 IE/ml (Actrapid, NovoNordisk
100 IE/ml), 10−6 M T3 thyroid hormone, 3×10−6 M mifepristone
(RU486), 3% human serum (type AB, male) and 1 mg/ml transferrin
(all from Sigma). Erythroid differentiation of the progenitors was
monitored by accumulation of haemoglobin and size decrease (not
shown).
2.2. Real Time PCR analysis
RNA was extracted from testis, various cancer cell lines and
erythroid progenitor cells with TRIZOL according to standard
procedures, subjected to DNAse I treatment and puriﬁcation with
the RNeasy MinElute Cleanup Kit (Qiagen) and reverse transcribed
with random hexamers and Superscript III (Invitrogen). All cDNA
samples were normalized at 10 ng/μl (40 ng/20 μl reaction). To assess
the expression of SRPK1 and SRPK1a the following assays were
designed with the Primer Express 3.0 software (Applied Biosystems):
for SRPK1a (120 bp amplicon), sense primer: 5'-CTCCACATTCGCCCTT-
CATC-3', antisense: 5'-CCTCGGTGCTGAGTTTCAGAT-3', probe: FAM-
ATCCCTCTCTCCTGCAGTG-MGB; for SRPK1 (100 bp amplicon),
sense primer: 5'-CACCATGGAGCGGAAAGTG-3', antisense: 5'-
GCCTCGGTGCTGAGTT TCAG-3', probe: FAM-CCCGAAAGAAAAG-
GACCA-MGB. Reactions were run in an ABI7500 real time PCR system
equipped with the SDS software v1.4 (Biosolutions, Athens, GR). For
normalization, we used GUSB in assays with testis and various cancer
cell lines and CSNK1D in assays with primary erythroid cells. Based on
the equal efﬁciency of the PCR assays (Supplementary Fig. 1), relative
quantitation of SRPK1/SRPK1a mRNA was assessed with the 2−dCt
method, while relative changes of the two isoforms in K562-SRPK1a
cells as compared to parental K562 cells were calculated automatically
using the 2−ddCt method. In addition, the 2−ddCt method was used to
evaluate the relative changes of SRPK1/SRPK1a mRNA during
differentiation as compared to day 0 (start of differentiation), and
also in K562 cells electroporated with a plasmid that expresses a short
hairpin RNA targeting SRPK1 as compared to cells electroporated with
a control construct. Samples were run in triplicate.
2.3. Construction of K562-SRPK1a stable cell line
For stable overexpression of SRPK1a in K562 cells, the pCMV2-
FLAG-SRPK1a-IRES-EGFP plasmid was constructed. For this, the
pIRES2-EGFP vector was digested with SalI and XbaI. A 1300-bp
fragment was puriﬁed and cloned into the SalI/XbaI site of pCMV2-
FLAG-SRPK1a plasmid [2]. K562 cells were co-electroporated with the
pCMV2-FLAG-SRPK1a-IRES-EGFP plasmid and an empty pcDNA3-
Neor plasmid (Invitrogen). To this end, 5×106 cells were resuspended
in 500 μl OptiMem medium (Invitrogen) supplemented with 10% FCS
and transferred to a 4-mm electroporation cuvette. After addition of
plasmid DNA (10 μg of pCMV-FLAG-SRPK1a-IRES-EGFP plasmid and
1 μg of pcDNA3-Neor plasmid), cells were electroporated at 260 V and
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allowed to recover for 48 h before addition of 500 μg/ml of the
neomycin analogue G418 (Sigma). After 10 days of selection under
G418, EGFP positive cells were sorted using a FACS-Vantage ﬂow
cytometer cell sorter (Becton Dickinson). After two additional weekly
cell sorts for highly EGFP positive cells, the obtained cell line was
named K562-SRPK1a. Cells were routinely analysed for EGFP
expression and remained stable for more than 4 months.
2.4. Flow cytometric analysis of SRPK1a expression
K562 and K562-SRPK1a cells were processed for intracellular
staining of over-expressed SRPK1a using anM5 anti-FLAGmonoclonal
antibody (Sigma) directed against the FLAG peptide sequence on the
N-terminus of introduced SRPK1a. Brieﬂy, cells (2×106 per staining)
were ﬁxed in 2% paraformaldehyde for 15 min at 4 °C, followed by
permeabilization in 70% ethanol for 30 min at −20 °C. Next, both
parental K562 and K562-SRPK1a cells were stained using an
unconjugated M5 anti-FLAG antibody (1 μg/100 μl cells in PBS) for
15 min at 4 °C. Following this, cells were washed twice and stained
using a goat-anti-mouse (GAM) phycoerythrin (PE)-labelled second-
ary antibody (1 μg/100 μl cells in PBS) for 15 min at 4 °C. Finally, cells
were washed, resuspended in PBS and analyzed on a FACScan ﬂow
cytometer (Becton Dickinson) for EGFP expression (FL1-ﬂuorescence)
and SRPK1a over-expression (FL2-ﬂuorescence). Data were analysed
using WinMDI software.
2.5. Clonogenicity assay
K562 and K562-SRPK1a cells were harvested, washed three times
in RPMI medium supplemented with 10% FCS, and plated (1000 cells)
in 3 ml serum-free or serum-containing (10% FCS) 0.9% methylcellu-
lose medium in 6-well plates with or without addition of 2 U/ml
erythropoietin (EPO), following a previously optimized protocol [26].
The cultures were microscopically scored for colony formation after
14 days at 37 °C in 5% CO2 in a fully humidiﬁed incubator. All
experiments were performed in triplicate.
2.6. Creation of siRNA-encoding constructs
Plasmids encoding siRNAs targeting SRPK1 were generated using
the siSTRIKE U6 Hairpin Cloning System (Promega) as described
previously [27]. Brieﬂy, sh4-SRPK1 encodes a siRNA targeting
nucleotides 648 to 665 (5'-GATCATCAAATCCAATTA-3') of the
human SRPK1 mRNA (NM_003137.3), while scr-SRPK1 encodes a
scrambled version of this sequence (5'-ATCTACATGCATCATAA-3') and
was used as control. Both the SRPK1 targeted and the control
nucleotide, eventhough used before, were aligned against the
Genebank database sequences to ensure speciﬁcity. Plasmids were
puriﬁed using the Qiagen MaxiPrep protocol (Qiagen).
2.7. Immunoﬂuorescence microscopy
Cells were collected by centrifugation, washed 3 times with
phosphate-buffered saline (PBS) and allowed to adhere to Alcian
blue-treated coverslips for 1 h. The samples were then ﬁxed with 1%
formaldehyde in PBS, permeabilized with 0.2% Triton X-100 and
blocked with 0.5% ﬁsh skin gelatin. DNA staining (propidium iodide)
and probing with the relevant primary (anti-SRPK1, anti-FLAG, both
diluted 1:150) and secondary (FITC-conjugated goat anti-mouse,
diluted 1:400; TRITC-conjugated goat anti-mouse, diluted 1:350)
antibodies, was performed according to Maison et al. [28]. All
secondary antibodies were purchased from Molecular Probes.
Samples were visualized in a Leica SP confocal microscope.2.8. Cell fractionation, western blotting and immunoprecipitation assays
Approximately 5×106 cells were harvested by centrifugation at
150g for 15 min, washed in phosphate-buffered saline (PBS),
resuspended in 500 μl of ice-cold buffer A (10 mM Hepes-KOH pH
7.5, 10 mM KCl, 1.5 mMMgCl2, 0.5 mM DTT) and allowed to stand for
10 min at 4 °C. The cells were then collected by centrifugation as
before, suspended in 200 μl of buffer A and lysed by 15 strokes of a
glass Dounce homogenizer. The homogenate was centrifuged for
10 min at 4300g to yield a supernatant (S1) and a crude nuclear
fraction. S1 was carefully decanted, mixed with 22 μl (0.1 volume) of
buffer B (300 mM Hepes-KOH pH 7.5, 1.4 M KCl, 30 mM MgCl2) and
centrifuged at 10,000g for 10 min to yield a pellet (that practically did
not contain any SRPKs) and a supernatant that was further
fractionated into cytoplasmic (S100) andmicrosomal (P100) fractions
by centrifuging at 100,000g for 60 min at 4 °C. The P100 pellets were
resuspended in buffer A. The crude nuclear fraction was resuspended
in 100 μl buffer A and laid onto a 1.2 ml cushion of 0.8 M sucrose in
buffer A. After centrifugation at 4300g for 10 min, the pellet (puriﬁed
nuclei) was collected, washed twice with PBS and further fractionated
according to the protocol described by Jiang et al. [29] to yield a
soluble nucleoplasmic, a DNAse extracted and a remaining insoluble
nuclear matrix fraction. Gel loading was adjusted to give equivalent
cell numbers in each lane. Endogenous SRPK1/SRPK1a were detected
by Western blotting, using an anti-SRPK1 monoclonal antibody
recognizing both isoforms (BD Biosciences), while the M5 anti-FLAG
monoclonal antibody was used for the detection of overexpressed
FLAG-SRPK1a. To test the purity of the individual compartments a
mouse monoclonal α-CREB (Cell Signaling) a polyclonal anti-lamin
(α-L1) (kindly provided by Spyros Georgatos, Medical School,
University of Ioannina) and a polyclonal antibody to ribosomal
protein S6 (Acris Antibodies GmbH) were used.
Immunoprecipitations were performed with polyclonal antibodies
against SRPK1 (recognizing both isoforms) and speciﬁcally against the
N-terminal extended domain of SRPK1a [2]. In vitro phosphorylation
assays were performed on beads as described previously using as
substrate the N-terminal domain of LBR fused to GST (GST-LBRNt) [8].
Incorporation of radioactivity was measured by excising the respec-
tive radioactive bands from an SDS-PAGE gel and scintillation
counting. RS kinase activity was expressed as total units (%).
For detecting hemoglobin or phosphorylated SR proteins, cells
were lysed with 200 μl of 1% Triton buffer (1% Triton X-100, 50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 10 μg/ml aprotinin, and 1 mM PMSF)
for 30 min on ice and passed 10 times through a 27-gauge needle. Cell
extracts were clariﬁed by centrifugation at 13,000g for 15 min in a
microcentrifuge. Hemoglobin was detected by Coomassie blue
staining, while the identity of phosphorylated SR proteins was
conﬁrmed by western blotting using the mAb104 monoclonal
antibody (culture supernatant, kindly provided by Jamal Tazi, Institut
de Génétique Moléculaire, C.N.R.S., Montpellier, France).2.9. Immunoprecipitation of SRPK1a-associated proteins, mass
spectrometry and data analysis
Approximately 108 K562-SRPK1a cells were lysed with 1.2 ml of
1% Triton buffer. The lysate was clariﬁed by centrifugation, precleared
by incubating with protein A-Sepharose for 3 h at 4 °C and
immunoprecipitated with the anti-FLAG monoclonal antibody.
Immunoprecipitates were analyzed by one-dimensional SDS-PAGE
and stained with Coomassie blue. Speciﬁc bands were excised from
the gel, cut into three pieces of equal size, washed, reduced, alkylated,
and subjected to in-gel digestion with porcine trypsin as previously
described [30]. Prior to analysis by nanoLC-MSMS, the generated
peptides were puriﬁed and concentrated using ZipTips (Millipore,
Bedford, MA) according to the manufacturer's instructions.
1322 I. Sanidas et al. / Biochimica et Biophysica Acta 1803 (2010) 1319–1331Tryptic peptides were separated by nanoﬂow reversed phase-C18
chromatography on a Tempo 1D nanoLC system (Applied Biosystems)
using a 90 min linear organic gradient on a 75 μm×15 cm RP-C18
column. The eluent was analyzed on a hybrid triple quadrupole/linear
ion trap mass spectrometer (4000 Q TRAP™ LC/MS/MS System,
Applied Biosystems) equipped with a nanoDCI source and operated in
information-dependent acquisition mode. An electrospray voltage of
2800 V, an interface heater temperature of 150 °C and a cone voltage
of 60 V were used. The collision energy was dynamically adjusted
according to the charge state and Mr of the precursors. Up to six MS/
MS spectra per experimental cycle were acquired, resulting in an
average duration of 3.6 s per cycle. Proteins were identiﬁed using the
ProteinPilot 2.0.1 software with the PSPEP 0.99 Tool for false discovery
calculation against a human International Protein Index protein
sequence database (IPI, version 3.54, European Bioinformatics
Institute, www.ebi.ac.uk/IPI/).
3. Results
3.1. Relative expression of SRPK1 and SRPK1a in various cancer cell lines
SRPK1 was originally puriﬁed and cloned from HeLa cells on the
basis of its ability to phosphorylate members of the SR family of
splicing factors [6,7], while SRPK1a was cloned from a human testis
cDNA library and its extended N-terminal domain of 171 aminoacids
was found to bind to the nuclear scaffold-associated protein SAFB1
[2]. To further probe into the biological function(s) of SRPKs, and if
possible to discern the cellular activities displayed by the two
isoforms, we ﬁrst decided to assess the relative expression ratio of
SRPK1/SRPK1a in various cancer cell lines, as well as in human testis
that express high levels of SRPK1 [4]. To this end we performed
relative quantitation analysis for the presence of SRPK1/SRPK1a
transcripts in testis, HeLa, K562, Molt-4 and HL-60 cells. We choseFig. 1. Relative expression of SRPK1 and SRPK1a in various cancer cell lines. (A) Schematic r
primers used for Real Time PCR analysis (S1 and S2, sense primers; A1 and A2, antisense prim
of sh4-SRPK1 and the relative position of the probe used for Northern blotting analysis. (B) R
was assessed with the 2−dCt method, based on equal efﬁciencies of the ampliﬁcation protoc
were done in triplicate, bars denote standard deviation.three leukaemia cell lines (K562, Molt-4 and HL-60 cells), since data
from the Gene Expression Atlas databank (http://expression.gnf.org/
cgi-bin/index.cgi), as well as from Northern blotting analysis,
substantiate the high levels of expression of SRPK1 in different
hematopoietic cell lines (Supplementary Fig. 2). In all cases, SRPK1
was by far the predominant isoform, with the relative ratio of SRPK1/
SRPK1a mRNA ranging from 250 to 480 (Fig. 1). K562 cells express
relatively high levels of SRPKs and therefore, we decided to use them
in our subsequent studies. Our decision was also prompted by the fact
that K562 cells have been largely employed in the past as a model
system to study differentiation as well as to determine the therapeutic
potential of new differentiating compounds.
3.2. Stable overexpression of SRPK1a promotes erythroid differentiation
of K562 cells
In an attempt to bring to light the role of SRPK1a we decided to
stably overexpress it in K562 cells. To this end we constructed the
pCMV2-FLAG-SRPK1a-IRES-EGFP plasmid (see Materials and meth-
ods). The Internal Ribosome Entry Site (IRES) of the encephalo-
myocarditis virus (ECMV) permits the translation of both FLAG-
SRPK1a and EGFP from a single bicistronic mRNA. K562 cells stably
overexpressing SRPK1a and EGFP were selected by combined
antibiotic selection and cell sorting as described in Materials and
methods. Using ﬂow cytometric analysis, it was shown that the
majority (at least 70%) of the cultured K562-SRPK1a cell population
expressed EGFP and could be co-stained with an anti-FLAG monoclo-
nal antibody (Fig. 2A), while a FLAG-immunoreactive band was
clearly visible in cell extracts of K562-SRPK1a cells (Fig. 2C, left panel).
Immunoprecipitations using the speciﬁc anti-SRPK1a polyclonal
antibody, followed by immunoblotting analysis of the immunopreci-
pitates with the anti-FLAG antibody, further conﬁrmed the over-
expression of SRPK1a (Fig. 2C, right panel). In addition, Real Time PCRepresentation of human SRPK1a and SRPK1. Arrows indicate the relative position of the
ers, see the respective sequences inMaterials andmethods). Bars indicate the target site
elative quantitation of SRPK1 versus SRPK1amRNA in testis and various cancer cell lines
ols for both targets. A ready-made GUSB assay was used for normalization. Experiments
Fig. 2. Analysis of SRPK1a overexpression in K562 cells. (A) Flow cytometric intracellular detection of overexpressed FLAG-SRPK1a (Y axis) and EGFP (X axis) on parental K562 (left
dot plot, negative control) and on genetically modiﬁed K562-SRPK1a cells (right dot plot). The majority of the parental cells were found in the lower left FLAG-SRPK1a(−)/EGFP(−)
quadrant, whereas the majority of the K562-SRPK1a cells were found in the upper right FLAG-SRPK1a(+)/EGFP(+) quadrant. (B) Relative quantitation of the mRNA of the two
isoforms in K562-SRPK1a cells as compared to parental K562 cells were calculated using the 2−ddCt method. A ready-made GUSB assay was used for normalization. Experiments were
done in triplicate, bars denote standard deviation. Black columns, SRPK1a; shaded columns, SRPK1. (C) Detection of overexpressed FLAG-SRPK1a in parental and K562-SRPKa cells by
immunoblotting analysis. Three hundred micrograms of lysates from parental and K562-SRPK1a cells, respectively, were analyzed on 10% SDS-polyacrylamide gels. The proteins
were then transferred to nitrocellulose, and FLAG-SRPK1a was detected with the M5 anti-FLAG monoclonal antibody (left panel). In the right panel lysates from K562-SRPK1a cells
were ﬁrst immunoprecipitated with the anti-SRPK1a polyclonal antibody and the immunoprecipitate was subsequently immunoblotted with the anti-FLAG antibody.
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with the 2−ddCt method, revealed a four-fold decrease of the SRPK1/
SRPK1a transcript ratio in K562-SRPK1a cells as compared with
parental K562 cells (Fig. 2B). Overexpression of SRPK1a also enhanced
to some extent the expression of SRPK1 in K562-SRPK1a cells, most
likely because part of the overexpressed SRPK1a underwent splicing.
The effects of SRPK1a overexpression in K562 cells were studied by
monitoring proliferation and clonogenicity as well as by recording
both cellular morphology and phenotype. The SRPK1a overexpressing
cells were found to be notably growth-retarded as compared to their
control counterparts (Fig. 3A). In addition, a signiﬁcant amount of
cells were smaller as compared to the parental K562 cells. Interest-
ingly, the pellets of K562-SRPK1a cells were strikingly more red as
compared to the parental cells, indicating the production of
hemoglobin. The induced synthesis of hemoglobin was evident by
staining the cells with a benzidine-peroxide solution (Fig. 3B) and also
by SDS-PAGE analysis of cell extracts from parental and K562-SRPK1a
cells, followed by Coomassie blue staining (Fig. 3C).
The outcome of SRPK1a overexpression in plating efﬁciency and
growth of K562 cells was subsequently studied by clonogenic assays.
In this respect, K562 and K562-SRPK1a cells were plated (1000 cells)
in serum-free or serum-containing methylcellulose medium in 6-well
plates in the presence or absence of 2 U/ml erythropoietin (EPO) (see
Materials and methods). The cultures were microscopically scored for
colony formation after 14 days. As shown in Fig. 3D, while EPO
induced K562 cell proliferation in serum-free medium, cells over-
expressing SRPK1a showed an extremely low proliferation potential
under the same conditions. In the presence of serum, the growth
potential of K562-SRPK1a cells was impaired to a lesser extent, withthe parental K562 cells being able to form 1.9 (in the absence of EPO)
to 2.4 times (in the presence of EPO) more colonies as compared to
K562-SRPK1a cells.
3.3. Decreased SRPK1 levels lead to erythroid differentiation of K562 cells
Small inhibitory RNAs targeting SRPK1 mRNA have been previ-
ously used with success to speciﬁcally reduce SRPK1 expression in
various cell lines, such as MiaPaCa2, Panc1, MCF7 and MCF10A cells
[27,31].
Transient transfection of one of these constructs, sh4-SRPK1
encoding a siRNA that targets nucleotides 648 to 665 of the human
SRPK1 mRNA (NM_003137.3), into K562 cells substantially reduced
SRPK1 expression as conﬁrmed by Western blot analysis (Fig. 4A).
No changes in SRPK1 levels were detected in cells transfected with
scr-SRPK1 encoding a scrambled version of the sh4 sequence
(Fig. 4A, ﬁrst lane). In agreement with the Western blot analysis,
immunoprecipitation experiments using the anti-SRPK1 polyclonal
antibody (recognizing both isoforms), followed by activity assays
showed that transfection of the siRNA-encoding construct resulted
in 75% inhibition of SRPK1 activity in K562 cells (Fig. 4B). Yet,
transfection of the same siRNA-encoding construct had a signiﬁ-
cantly weaker effect on SRPK1a activity as judged by immunopre-
cipitation experiments using the speciﬁc anti-SRPK1a polyclonal
antibody followed by activity assays. This was surprising, since sh4-
SRPK1 encodes a siRNA targeting a common sequence of SRPK1 and
SRPK1a mRNAs, within their spacer domain. To further substantiate
the rather speciﬁc knockdown effect of sh4-SRPK1 on SRPK1 we
performed Real Time PCR analysis. Relative quantiﬁcation of SRPK1
Fig. 3. Stable overexpression of SRPK1a promotes erythroid differentiation of K562 cells. (A) Growth rates of K562 and K562-SRPK1a cells. The total cell number was counted daily
and represents the mean of four different experiments, bars denote standard deviation (for day 1, day 2 and day 3: pb0.01 by Student t-test). (B) Exponentially growing K562 and
K562-SRPK1a cells were seeded at 1×105 cells/ml and left to grow for 1, 2 and 3 days respectively. The percentage of benzidine-positive K562 (black columns) and K562-SRPK1a
(shaded columns) cells was determined daily in order to quantify the proportion of hemoglobin-containing cells. The data reported represent the mean of three different
experiments, bars denote standard deviation. (C) One hundred micrograms of cell extracts from control K562, K562-SRPK1a and hemin/DMSO-treated cells were analyzed on 12%
SDS-polyacrylamide gels and then stained with Coomassie Brilliant Blue R-250. The arrow denotes the position of γ-globin. (D) K562-SRPK1a cells show reduced clonogenic
potential. Parental and K562-SRPK1a cells were plated in serum-free or serum-containing methylcellulose medium in 6-well plates in the presence or absence of 2 U/ml EPO. A
comparative presentation of the observed colonies number after 14 days of culture is shown. Black columns, K562 cells; shaded columns, K562-SRPK1a cells. All experiments were
done in triplicate, bars denote standard deviation.
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with the sh4-SRPK1 plasmid as compared to cells electroporated
with scr-SRPK1, revealed a decrease of the SRPK1/SRPK1a mRNA
ratio ranging from 1.09 on the ﬁrst day after transfection of sh4-
SRPK1 to 3.25 and 3.01 on the fourth and ﬁfth day after transfection
respectively (Fig. 4C). The observed diminished inhibition of SRPK1a
may be due to the fact that the extra segment of 513 bases at the
5'end drives SRPK1a mRNA to adopt a conﬁguration that hinders
the recognition of the targeted nucleotides by the siRNA.
K562 cells transiently transfected with sh4-SRPK1 exhibited a
phenotype similar to K562-SRPK1a cells, in that theywere smaller and
their growth rate was signiﬁcantly reduced as compared to control
K562 cells (cells transiently transfected with scramble siRNA).
Furthermore, cells transfected with sh4-SRPK1 were synthesizing
signiﬁcant amounts of hemoglobin as evidenced by staining the cells
with a benzidine-peroxide solution (Fig. 4D) and also by SDS-PAGE
analysis of cell extracts from K562 cells transfected with sh4-SRPK1
and scr-SRPK1, respectively, followed by Coomassie blue staining
(Fig. 4E). It can therefore be concluded that a decreased SRPK1/
SRPK1a ratio -arising either from down-regulating SRPK1 or over-
expressing SRPK1a- leads to erythroid differentiation of K562 cells.
3.4. A decreased SRPK1/SRPK1a ratio is observed in K562 cells
differentiated with hemin/DMSO and in human erythroid progenitor
cells
If down-regulation of SRPK1 or alternatively overexpression of
SRPK1a leads to erythroid differentiation of K562 cells, a similar
decrease in SRPK1/SRPK1a ratio should also be observed in K562 cells
induced to differentiate upon addition of hemin/DMSO. Indeed, as
shown in Fig. 5A, Real Time PCR analysis of RNA samples extractedfrom untreated K562 cells and cells incubated in the presence of
60 μM hemin and 1.5% DMSO, followed by relative quantitation of
SRPK1 and SRPK1a with the 2−ddCt method, revealed an impressive
decrease of the SRPK1/SRPK1a transcript ratio in hemin/DMSO-
treated K562 cells as compared to the untreated cells. Notably, the
observed decrease of the SRPK1/SRPK1a mRNA ratio was far more
pronounced on the ﬁrst day of differentiation (19.4-fold) and then
dropped to 8.2-, 6.8- and 2.6-fold, on the second, third and fourth day,
respectively, implying that it is closely related to the initial triggering
of leukaemic cells to differentiate (Fig. 5A).
In addition, if SRPK1a is engaged in erythroid differentiation then
human erythroid progenitor cells should also express relatively high
levels of SRPK1a. In primary erythroid cells, SRPK1 was still the
predominant isoform, yet the SRPK1/SRPK1a transcript ratio dropped
dramatically to 27 as compared to the value of 480 observed in K562
leukaemic cells (Fig. 5B), further suggesting that the decreased
SRPK1/SRPK1a ratio is probably associated with the commitment of
primary cells to differentiate. In line with this hypothesis, terminal
erythroid differentiation of the progenitor cells resulted in only a
further minor decrease of the relative SRPK1/SRPK1a mRNA expres-
sion as compared to the untreated cells. (Fig. 5C).
3.5. Overexpressed SRPK1a localizes in the microsomal fraction,
cytoplasm and nuclear matrix of K562-SRPK1a cells and does not
affect SR protein phosphorylation
SR proteins that mediate both constitutive and alternative splicing
of pre-mRNAs have been considered as the quintessential targets of
SRPKs [3,6]. In addition, a BCR/ABL-dependent change in pre-mRNA
processing together with an increase in SRPK1 expression were
observed in p210BCR/ABL-eGFP-transduced umbilical cord blood
Fig. 4. Down-regulation of SRPK1 levels lead to erythroid differentiation of K562 cells. (A) K562 cells were transfected with either 2.5, 5, 7.5 and 10 μg of sh4-SRPK1 constructs or
10 μg of the scr-SRPK1 construct that encode a siRNA targeting the SRPK1 transcript or a scrambled version of this sequence, respectively. Western blot analysis was then performed
on transfectants to determine their effects on the expression of SRPK1. (B) Immunoprecipitations from cell extracts derived from K562 cells transfected with scr-SRPK1 (10 μg) or
sh4-SRPK1 (7.5 and 10 μg, respectively) were performedwith an anti-SRPK1 polyclonal antibody (recognizing both isoforms) and a speciﬁc anti-SRPK1a polyclonal antibody and the
immunoprecipitates were assayed for RS kinase activity, using the N-terminal domain of LBR fused to GST (GST-LBRNt) as substrate. The samples were analyzed by SDS-PAGE and
autoradiographed. The bands corresponding to full-length labeled GST-LBRNt are shown (left panel). The radioactive bands were excised, and the radioactivity was determined by
Cerenkov counting (right panel). Data are presented as % relative activity of sh4-SRPK1 transfected K562 cells. The activity of scr-SRPK1 transfected cells was set to be 100. Bars
denote standard deviation. Shaded columns, scr-SRPK1 transfected; black columns, sh4-SRPK1 transfected (7.5 μg); open columns sh4-SRPK1 transfected (10 μg). (C) Relative
quantitation of SRPK1/SRPK1a mRNA in K562 cells electroporated with the sh4-SRPK1 plasmid as compared to cells electroporated with scr-SRPK1 were calculated 1, 2, 3, 4 and
5 days after transfection using the 2−ddCt method. A ready-made GUSB assay was used for normalization. Experiments were performed in triplicate, bars denote standard deviation.
Black columns, SRPK1a; shaded columns, SRPK1. (D) The percentage of benzidine-positive scr-SRPK1 transfected (shaded columns) and sh4-SRPK1 transfected K562 cells (black
columns) were determined 3, 4 and 5 days after transfection in order to quantify the proportion of hemoglobin-containing cells. The data represent the mean of three different
experiments, bars denote standard deviation. (E) One hundred micrograms of cell extracts from scr-SRPK1 (10 μg) and sh4-SRPK1 (10 μg) transfected cells were analyzed on 12%
SDS-polyacrylamide gels and then stained with Coomassie Brilliant Blue R-250. The arrow denotes the position of γ-globin.
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SRPK1a had upon SR protein phosphorylation, we performedWestern
blotting analysis on cell lysates produced from control and K562 cells
overexpressing SRPK1a, using the mAb104 monoclonal antibody.
mAb104 binds a conserved phosphoepitope on the family of SR
proteins, consisting of the consecutive RS dipeptides [33]. As shown in
Fig. 6 overexpressed SRPK1a did not enhance the level of SR proteinphosphorylation in K562-SRPK1a cells. On the contrary, a minor
decrease in the intensity of a band with molecular mass of ~35 kDa
and a more substantial reduction of a second band at 119 kDa were
observed.
The lack of increased SR protein phosphorylation suggested that
overexpressed SRPK1a may not distributed in the nucleus of K562-
SRPK1a cells. To examine the subcellular localization of FLAG-SRPK1a
Fig. 5. A decreased SRPK1/SRPK1a ratio is observed in hemin/DMSO-treated K562 cells and in human erythroid progenitor cells. (A) Relative quantitation of SRPK1/SRPK1amRNA in
K562 cells treated with hemin/DMSO for 1, 2, 3 and 4 days, respectively, as compared to parental K562 cells (day 0 of differentiation) were calculated using the 2−ddCt method. A
ready-made GUSB assay was used for normalization. Experiments were performed in triplicate, bars denote standard deviation. Black columns, SRPK1a; shaded columns, SRPK1.
(B) Relative quantitation of SRPK1 versus SRPK1amRNA in K562 and erythroid progenitor cells was assessed automatically with the 2−dCt method, based on equal efﬁciencies of the
ampliﬁcation protocols for both targets. A ready-made CSNK1D assay was used for normalization. Experiments were performed in triplicate, bars denote standard deviation.
(C) Relative quantitation of SRPK1/SRPK1a mRNA in primary erythroid cells induced to differentiate (see Materials and methods) for 3, 4, 5 and 6 days, respectively, as compared to
untreated cells (day 0 of differentiation) were calculated using the 2−ddCt method. A ready-made assay CSNK1D was used for normalization. Experiments were performed in
triplicate, bars denote standard deviation. Black columns, SRPK1a; shaded columns, SRPK1.
Fig. 6. Overexpression of SRPK1a does not impact SR protein phosphorylation. Three
hundred micrograms of lysates from control and K562 cells overexpressing SRPK1a,
respectively, were analyzed on 12% SDS-polyacrylamide gels. The proteins were then
transferred to nitrocellulose, and phosphorylated SR proteins were detected with the
mAb104 monoclonal antibody.
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control cells we initially employed immunoﬂuorescence microscopy.
As shown in Fig. 7A (left panel), in parental K562 cells, SRPKs
dispersed throughout the cell. Due to the large nuclei in K562 cells,
there is little cellular space corresponding to the cytoplasm, thereby
hampering deﬁnitive conclusions by immunoﬂuorescence microsco-
py. In this respect we next employed biochemical fractionation
methods. Brieﬂy, the cell lysate was centrifuged at 4300g at 4 °C for
10 min to yield a supernatant (S1) and a crude nuclear fraction. This
initial supernatant was further fractionated into cytoplasmic (S100)
and microsomal (P100) fractions by centrifuging at 100,000g for
60 min at 4 °C. Puriﬁed nuclei were isolated by passing the crude
nuclear fraction through a sucrose cushion and subjected to
sequential extraction steps with high salt and DNAseI. The residual
insoluble pellet was designated as the nuclear matrix fraction.
Western blotting analysis of the different fractions obtained, using
an anti-SRPK1 mouse monoclonal antibody that recognizes both
isoforms, showed a single immunoreactive band, at ~97 kDa (prob-
ably corresponding to SRPK1 due to the very low levels of SRPK1a), in
the S1 and nuclear fractions at roughly equivalent amounts (Fig. 7A,
right panel). The immunoreactive band detected in the S1 fraction
upon further fractionation was analyzed in two bands, one associated
with the cytoplasmic fraction (S100) and a stronger one associated
with the P100 fraction (Fig. 7A, right panel).
K562-SRPK1a cells exhibited a clearly different ﬂuorescence
pattern of total SRPKs (both endogenous and overexpressed), in
that a discernible extranuclear localization was observed, with the
nuclear staining being signiﬁcantly weaker as compared to the
parental cells (compare Fig. 7B, left panel with Fig. 7A, left panel).
The peripheral rim ﬂuorescence pattern was predominant when
Fig. 7. Localization of endogenous SRPKs and FLAG-SRPK1a in control and K562-SRPK1a cells. (A) Fluorescence pattern of SRPKs in parental K562 cells (left panel). SRPKs were
detected using the mouse monoclonal anti-SRPK1 antibody (FITC, green), while nuclei were stained with propidium iodide (PI). A dispersion of SRPKs throughout the entire cell is
clearly seen. The distribution of SRPKs between different subcellular compartments was analyzed by immunoblotting using the monoclonal anti-SRPK1 antibody (right panel). Cell
fractionation was performed as described in Materials and methods. The distribution of CREB, lamins, and S6 ribosomal protein was used as a marker to test the purity of the
individual compartments. A mouse monoclonal α-CREB, a polyclonal anti-lamin (α-L1) and a polyclonal α-S6 antibody were used for immunoblotting. (B) Fluorescence pattern of
total SRPKs (both endogenous and overexpressed, left panel) and FLAG-SRPK1a (middle panel) in K562-SRPK1a cells. SRPKs were detected using the monoclonal anti-SRPK1
antibody (TRITC, red), while overexpressed FLAG-SRPK1a was detected using the speciﬁc anti-FLAG monoclonal antibody (TRITC, red). SRPKs localized in the nucleus, while a
peripheral rim distribution pattern, was also seen. The peripheral, cytoplasmic distribution became predominant when cells were stained with anti-FLAG antibody, with a rather
minor fraction seen in the nucleus. The distribution of FLAG-SRPK1a was also analyzed by immunoblotting, following biochemical fractionation, using the anti-FLAG antibody (right
panel).
Fig. 8. Isolation and characterization of SRPK1a-associated proteins. SRPK1a-associated
complexes were isolated by immunoprecipitation of FLAG-SRPK1a from K562-SRPK1a
cells with the anti-FLAG monoclonal antibody. Before immunoprecipitation the cell
lysate was precleared by incubating with protein A-Sepharose. Immunoprecipitates
were analyzed by SDS-PAGE on a 12.5% gel followed by Coomassie blue staining. Lane 1,
protein bands derived from the anti-FLAG monoclonal antibody; lane 2, proteins co-
immunoprecipitated with FLAG-SRPK1a. Speciﬁc bands were excised from the gel,
subjected to in-gel protease digestion and analyzed by reversed-phase LC-MSMS. The
resulting peptide fragment ﬁngerprints were matched against a human protein
sequence database. Gel bands are annotated with the identity of the proteins found
in the corresponding in-gel digests. Bars on the left indicate molecular masses (in kDa).
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antibody, while a rather weak speckled pattern was also seen in the
nucleus (Fig. 7B, middle panel). Biochemical fractionation methods
conﬁrmed the immunoﬂuorescence data. Western blotting analysis,
using the anti-FLAG monoclonal antibody, showed a strong immuno-
reactive band in the S1 fraction, which, similarly to the control cells,
upon further fractionation was distributed between the P100 and
S100 fractions, and a weaker one in the nuclear matrix fraction
(Fig. 7B, right panel). These data clearly demonstrate that over-
expressed SRPK1amainly localized in themicrosomal fraction and the
cytoplasm, and to a lesser extent in the nuclear matrix.
3.6. Puriﬁcation and characterization of SRPK1a-associated complexes
In an attempt to identify proteins speciﬁcally associated with
SRPK1a, we immunopuriﬁed FLAG-tagged SRPK1a from extracts of
stably transfected K562 cells and identiﬁed the co-puriﬁed proteins by
MS/MS based mass spectroscopy (Fig. 8). The known functions of
these proteins as well as their subcellular localization, as extracted
from the NCBI database, are listed in Table 1. More detailed data on
molecular weight, accession No, peptide hit number and the amino
acid sequence of identiﬁed peptides of the SRPK1a-interacting
proteins are provided in Supplementary Table 1. Almost the entirety
of the identiﬁed proteins were RNA-binding proteins localized both in
the nucleus and the cytoplasm. Numerous RNA helicases, heteroge-
neous nuclear ribonucleoproteins, ribosomal proteins, and mRNA-
associated proteins were found and among them several had been
previously identiﬁed in ribosomal and pre-ribosomal complexes. As
listed in Table 2, of the twenty-one proteins identiﬁed in our SRPK1acomplex, nine were previously identiﬁed as components of the
human Nop56p-associated pre-ribosomal RNP complex involved in
ribosome biogenesis [34], nine were found associated with the
nucleolin protein complex that may be actively involved in ribosome
biogenesis and maturation [35], three were found associated with the
Table 1
Components of the SRPK1a protein complex. The known functions of proteins in
humans and their subcellular localization were extracted from the NCBI database.
Protein Known function in humans Subcellular
localization




MOV10 Moloney leukaemia virus 10 homolog, putative
RNA helicase
cytoplasm





pre-mRNA processing, mRNA metabolism and
transport, binds scaffold-attachment regions of
genomic DNA
nucleus
Nucleolin nucleolar phosphoprotein, involved in the
synthesis and maturation of ribosomes
nucleus, cell
cortex




DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21,
RNA helicase
nucleus
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4,
involved in the peroxisomal beta-oxidation
pathway for fatty acids
mitochondrion,
peroxisome
PABPC1 poly(A) binding protein, required for poly(A)
shortening and translation initiation
cytoplasm,
nucleus
HNRNPM pre-mRNA processing, mRNA metabolism and
transport
nucleus
IGF2BP1 insulin-like growth factor 2 mRNA binding














Vimentin intermediate ﬁlament protein, maintaining cell




YBX1 Y box binding protein 1, binds RNA, dsDNA,





ribosomal protein assembly and transport,








HNRNPC pre-mRNA processing, mRNA metabolism and
transport
nucleus








RALY RNA binding protein, autoantigenic (hnRNP-




Previously identiﬁed protein complexes containing components of the SRPK1a protein
complex Nop56p: Nop56p-associated pre-ribosomal ribonucleoprotein complex
involved in ribosome biogenesis [34]; NucPC: Nucleolin Protein Complex, that might
be involved in ribosome biogenesis and maturation [35]; NPC: Nucleophosmin Protein
Complex that mediates nuclear export of mammalian ribosome [36]; LMC: Large
Microprocessor Complex that mediates the genesis of miRNAs and might also mediate
preribosomal RNA processing [37,38]; myc: complex that controls c-myc mRNA
stability [39].
Nop56p NucPC NPC LMC myc
DHX9 + + + +
MOV10
MATR3
HNRNPU (SAF-A) + + + +










YBX1 + + +
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nuclear export of mammalian ribosomes [36] and three were
identiﬁed as components of the large Drosha complex that was
proposed to mediate preribosomal RNA processing ([37,38], see also
Biomolecular Interaction Network Database). Furthermore, ﬁve
proteins of the SRPK1a complex were previously identiﬁed to be
part of a complex that regulates c-myc mRNA stability [39].
Interestingly, DHX9 helicase, HNRNPU (SAF-A), nucleolin, HNRNPM,
YBX1 and nucleophosminwere identiﬁed in at least three of the above
complexes, while SRPK1a itself has been reported to be a component
of both the Nop56p and large Drosha complexes (Table 2), demon-
strating the effectiveness of our proteomic approach.
Although we have been unable to identify the actual substrates of
SRPK1a, since none of the SRPK1a-associated proteins contained an RS
domain and therefore could not be directly phosphorylated by the
kinase, our data point to the conclusion that SRPK1a is associated with
ribosome assembly and function and furthermore that it is via thisparticular function that SRPK1a promotes erythroid differentiation in
K562 cells.
4. Discussion
SRPK1a has been cloned in 2001 [2] but has received minimal
attention up to now. SRPK1a escaped notice because of its very low
expression levels and difﬁcult detection. The extra segment of SRPK1a
shows a loop structure at the RNA level, with extended double-
stranded domains (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi; E.
Nikolakaki, unpublished observations) resulting in poor detection by
Northerns and RT-PCRs. In this respect, and after several tests, we
found that only when using sense primers from the 3' region of intron
I (spliced out in SRPK1), very close to the common sequence (see
Materials and methods), we observe efﬁcient ampliﬁcation. Further-
more, the antigenicity of the extended N-terminal domain of the
protein is very low, rendering all our efforts to raise speciﬁc peptide
antibodies unsuccessful. The only available antibody so far was raised
against the whole N-terminal domain of SRPK1a fused to GST and is
functional only in immunoprecipitations.
A variety of roles and functions have been attributed exclusively to
SRPK1, while the contribution of SRPK1a to these diverse functions
remains largely unknown. In the present study, using K562 cells as a
model system, we found that the ratio of SRPK1 to SRPK1a is critical in
determining K562 cell fate, with SRPK1 favouring proliferation and
SRPK1a favouring differentiation. Our data are in line with previous
reports indicating that SRPK1 levels were up-regulated in pancreatic,
breast and colonic tumors where its expression increased coordi-
nately with tumor grade [27,31]. Furthermore, it was shown that high
levels of expression of SRPK1 were associated with resistance of
various cell lines to chemotherapeutic agents such as oxaliplatin,
gemcitabine and cisplatin [27,31,40].
An important issue arising from these ﬁndings are the functional
differences between SRPK1 and SRPK1a that might account for the
association of high SRPK1 levels with proliferation in contrast to the
reduction in proliferation and induction of erythroid differentiation
followed by stable SRPK1a overexpression in K562 cells. Except for the
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exhibit the same speciﬁcity, as judged by their ability to phosphor-
ylate various derivatives of the NH2-terminal domain of LBR, in which
one or more serines of the RS domain were mutated to Gly or Ala [2].
Furthermore, both SRPK1 and SRPK1a were able to induce alternative
splicing of human tau exon 10 in transfected cells [2], while, as shown
in the present study, overexpression of SRPK1a had no signiﬁcant
effect upon SR protein phosphorylation. Differential localization and
the consequent targeting of speciﬁc substrates might therefore be the
reason for their distinct cellular functions. SRPK1 distributed almost
equally between the nucleus and the extranuclear space of control
K562 cells, whereas only a small amount of SRPK1a exhibited nuclear
localization, andwas associatedwith the nuclearmatrix. It is therefore
possible that the nuclear localization of SRPK1 accounts for its
implication in several key events related to the proliferation potential
of human leukaemic cells. These key events may or may not relate to
phosphorylation regulation of pre-mRNA processing. In this respect,
SRPK1 may phosphorylate substrates that are not related to pre-
mRNA splicing, such as LBR, thereby regulating the attachment of
chromatin to the nuclear periphery [16,17] and/or other yet
unidentiﬁed substrates.
Interestingly, the majority of SRPK1a was found associated with
the microsomal (P100) fraction, while a considerable amount of
extranuclear SRPK1 was also found associated with the same fraction.
Whether the microsomal association of SRPKs in K562 cells is cell
type-speciﬁc or represents a more general localization pattern,
applicable to other cell lines as well, remains at present unknown
and represents an interesting subject for future studies. In keeping
with the latter possibility, Wang et al. reported that both SRPK1 and
SRPK2 were found to localize in the cytoplasm of adherent cells but in
a nondiffused fashion, with the underlying cytoplasmic structure
remaining to be characterized [5]. Furthermore, the predominant
association of SRPK1a with the P100 fraction, but also its presence at
the nuclear matrix (the nucleolus, where ribosome biogenesis gets
under way, is considered as being part of the nuclear matrix)
corroborates well with the data from mass spectrometric analysis of
immunopuriﬁed SRPK1a-associated complexes. SRPK1a complexes
were shown to contain a variety of RNA-binding proteins, such as RNA
helicases, heterogeneous nuclear ribonucleoproteins, ribosomal pro-
teins, and mRNA-associated proteins, the majority of which are
known players in ribosome processing and function, and have been
previously identiﬁed in ribosomal and pre-ribosomal complexes. It is
therefore possible that SRPK1a mainly -but SRPK1 as well to some
extent- may be associated with polysomes. Preliminary data conﬁrm
that SRPK1a associates with ribosomes in K562-SRPK1a cells, thereby
suggesting that the kinase may have an active role in ribosome
function and/or structure (data not shown).
An important question is whether the observed interactions are
speciﬁc for SRPK1a. In this regard it should be pointed out that despite
our efforts we have been so far unable to generate a K562 cell line
overexpressing SRPK1, while even transient overexpression of SRPK1
in K562 cells was inefﬁcient. Preliminary proteomic analysis of the
SRPK1-associated proteins in control K562 cells revealed that some of
the proteins found associated with SRPK1a bind also to SRPK1
(IGF2BP1, SYNCRIP, HNRNPA2B1 and HNRNPC), whereas others not
(data not shown). We have not detected any of the proteins
previously identiﬁed to be part of the Nop56 and the large Drosha
complexes. The association of these proteins seem to be more speciﬁc,
taking also into consideration that the proteomic analyses performed
by the groups who characterized the large Drosha and the Nop56
complexes lead to the identiﬁcation exclusively of SRPK1a and not of
both isoforms [34,37].
Several reports document a link between ribosomal function and
erythroid differentiation in human leukaemic cells. First, mutations in
several ribosomal proteins lead to Diamond–Blackfan anemia, a
syndrome characterized by defective erythropoiesis, congenitalanomalies, and increased frequency of cancer [41]. Second, when
K562 cells were induced to differentiate by dimethyl sulfoxide and
hemin, the observed differentiation was accompanied by a rapid
increase in the rRNA levels [42]. In a similar study, activation of
ribosomal gene clusters has been observed in hemin-induced K562
cells, 48 h after hemin induction [43]. Third, erythroid precursor cells,
a primitive cell population which precedes the appearance of
deﬁnitive erythroid elements, and early erythroid cells were shown
to be engaged mainly in ribosomal production, including synthesis of
rRNA and ribosomal proteins [44].
Unluckily, the speciﬁc substrates targeted by SRPK1a remain
unknown at present, since none of the SRPK1a-associated proteins
identiﬁed by mass spectrometric analysis was found to contain an RS
domain. The lack of these critical data make difﬁcult to directly
address the question of how SRPK1amediates differentiation of K562-
SRPK1a cells. An interesting hint that could potentially link the
SRPK1a partners with ribosomal assembly and protein synthesis as
well as with the transcription of speciﬁc genes that are critical to
differentiation is the observation that ﬁve proteins of the SRPK1a
complex were previously implicated in regulating c-myc mRNA
stability [39]. c-myc seems to play a critical role in coordinating
protein synthesis through the transcriptional control of RNA and
protein components of ribosomes, and also of gene products required
for the processing of ribosomal RNA, the nuclear export of ribosomal
subunits and the initiation of mRNA translation [45]. Yet, when we
tested the c-myc mRNA levels by Real-Time PCR in control and K562-
SRPK1a cells we were unable to detect any signiﬁcant difference (data
not shown). It is possible that the particular SRPK1a partners (DHX9,
HNRNPU, IGF2BP1, SYNCRIP and YBX1) may also regulate the stability
and/or translation of mRNA of other yet unknown regulatory proteins
involved in ribosomal assembly and function.
At this point it should be also noted that numerous proteins
originally thought to reside solely in the nucleolus, which is
considered as the “ribosome factory,” have been shown to continu-
ously shuttle from the nucleolus to various subcellular compartments
in a regulated manner ([36] and references therein) and exert diverse
functions. A typical example is nucleophosmin, a common component
of the nucleophosmin protein complex [36], the nucleolin protein
complex [35], the Nop56p-associated ribonucleoprotein complex
[34], and the SRPK1a complex. In line with its participation in all
the above protein complexes, nucleophosmin -besides residing in the
nucleolus- has been found in several other subnuclear destinations
[46–48] and was also shown to shuttle from the nucleus to the
cytoplasm in a CRM1-dependent manner [49]. Furthermore, besides
its well-documented role in ribosome biogenesis, nucleophosmin was
shown to regulate transcription [50], while in a certain type of chronic
lympocytic leukaemia (CLL) it was higly expressed in the cytoplasm
and was found associated with ribosomes [51]. A second example is
nucleolin, identiﬁed in the same protein complexes as nucleophos-
min. Nucleolin is found in various cell compartments, ranging from
the nucleolus, of which it is a major component, to the cell surface
[52]. Besides mediating the processing of ribosomal RNA, nucleolin
may function as a histone chaperone and a chromatin co-remodeler,
thereby regulating transcription. Furthermore, nucleolin was found
associated with CD154 mRNA (coding for a protein which is critical in
mediating immune responses) in both the ribonucleoprotein and
polysome fractions and is involved in the regulation of its rate of
turnover [53].
The identiﬁcation of the speciﬁc substrates of SRPK1a and the
delineation of how does this kinase with its associated proteins
mediate erythroid differentiation form the basis of the upcoming
studies. These studies not only will help deciphering the potential
involvement of SRPK1a in ribosome assembly and function but
more importantly will provide valuable insights on the molecular
machinery that directs erythroid differentiation in human leukaemic
cells.
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